CNDA Shopping Cart

Please leave this field blank.

Home My Account View Cart Checkout
PW53: Therapeutic Considerations for COVID-19
NW50: Chronic Fatigue Syndrome: Route to Resolution (self study)
2022 Virtual Conference: The Holistic Human: Advances in Naturopathic Primary Care
PW52: Ketamine: Therapeutic History & Current Research
NW51: Intestinal Parasites A New Approach to an Old Problem
PW50: Current Research with Psilocybin (self study)
PW51: Current Research with MDMA
NW49: Ayurvedic Medicine & Cardiology (self study)
PW49: Psychedelics & the Future of Medicine (self study)
PW48: Updates in Dermatology: Treating Hair Loss (self study)
PW51: Current Research with MDMA
PW51: Current Research with MDMA Storefront > Live Pharmacy Webinars

View larger image
PW51: Current Research with MDMA
Price: $95.00
Status: Available

Please leave this field blank.

Pharmacy Webinar 51

Tues, Jan. 25, 2022
6:30pm - 8:30pm Pacific

CNDA Members (& Members of Your State Association): Use Your Coupon Code (member) At Checkout

2 CEs*
2 CEs for CA LAc (pending)

*Approved by CNDA; pending approval by OBNM

Natalie Metz, ND, MA

Presentation Description

3,4-methylenedioxy-methamphetamine (MDMA) is a unique psychoactive substance known for its euphoric, empathogenic, and psychostimulant effects. It has been explored in psychotherapeutic contexts for over thirty years, having been first introduced to the therapeutic community by the pioneering psychedelic chemist Alexander “Sasha” Shulgin in the San Francisco Bay Area.

MDMA’s utility as a catalyst for transformative therapeutic work was recognized early on, and it was introduced to thousands of therapists who supported their patients’ growth and healing with psychotherapy-assisted MDMA sessions before it was placed in Schedule I by the DEA in 1985.

This scheduling of MDMA made it illegal to possess or utilize, and effectively ended all above ground therapeutic work, despite many efforts by clinicians and patients to advocate for its potential benefit.

In 1986, Rick Doblin formed the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research and educational organization that develops medical, legal, and cultural contexts to explore careful uses of psychedelics and cannabis.

In 2010, MAPS published the first randomized, controlled pilot study looking at the safety and efficacy of MDMA-assisted psychotherapy for patients with chronic, treatment-resistant posttraumatic stress disorder (PTSD), demonstrating excellent results. MDMA was granted “breakthrough therapy designation” by the FDA in 2017 and has continued to be studied in populations with PTSD, anxiety related to terminal illness, and more. These studies continue to demonstrate safety and efficacy, and the long term follow up data has shown lasting benefits after only a few treatments.

MDMA is currently being investigated in Phase 3 clinical trials in the US, and the mechanisms of action by which MDMA imparts its unique therapeutic effects continue to be explored. A review of past and current clinical research, the basic pharmacology of MDMA, and its unique neuromodulatory effects will highlight the therapeutic potentials of this unique molecule, pointing toward the need for more research and clinical applications.

This is the third of a series of webinars which will present an overview of psychedelic-assisted therapies.

Goals and Objectives:

  • After the presentation, participants will be able to confidently:
  • Understand basic neuroscience, pharmacology, and proposed therapeutic mechanisms of action of MDMA
  • Describe basic history of MDMA and use in therapeutic contexts
  • Demonstrate familiarity with past and current clinical trials exploring the therapeutic potentials of MDMA-assisted therapies
  • Review the outcomes of select clinical trials and long term follow up data with case studies, demonstrating the overall safety and efficacy of MDMA-assisted therapies